Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• RahibLSmithBDAizenbergRRosenzweigABFleshmanJMMatrisianLMProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United StatesCancer Res201474112913292124840647
   PubMed Web of Science ®Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• KoAHProgress in the treatment of metastatic pancreatic cancer and the search for next opportunitiesJ Clin Oncol201533161779178625918299
   PubMed Web of Science ®Google Scholar
• BurrisHAIIIMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• Gourgou-BourgadeSBascoul-MolleviCDesseigneFImpact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trialJ Clin Oncol2013311232923213101
   PubMed Web of Science ®Google Scholar
• Von HoffDPennyRShackSFrequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents [abstract 3071]J Clin Oncol200624Suppl 18138s
   Web of Science ®Google Scholar
• Von HoffDDRamanathanRKBoradMJGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialJ Clin Oncol201129344548455421969517
   PubMed Web of Science ®Google Scholar
• Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
   PubMed Web of Science ®Google Scholar
• AssafEVerlinde-CarvalhoMDelbaldoC5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinomaOncology2011805–630130621778770
   PubMed Web of Science ®Google Scholar
• BergerAKWeberTFJagerDSpringfeldCSuccessful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinomaOnkologie2013361276376524356569
   PubMedGoogle Scholar
• BertocchiPAbeniCMeriggiFGemcitabine plus nab-paclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysisRev Recent Clin Trials201510214214525881637
   PubMedGoogle Scholar
• LeeMGLeeSHLeeSJ5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapyChemotherapy201359427327924457620
   PubMed Web of Science ®Google Scholar
• PortalAPernotSSiauveNSustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategyClin Res Hepatol Gastroenterol2014382e23e2624559766
   PubMed Web of Science ®Google Scholar
• RahmaOEDuffyALiewehrDJSteinbergSMGretenTFSecond-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trialsAnn Oncol20132481972197923670093
   PubMed Web of Science ®Google Scholar
• OettleHRiessHStielerJMSecond-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trialJ Clin Oncol201432232423242924982456
   PubMed Web of Science ®Google Scholar
• GillSKoYCrippsMPANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy [abstract 4002]J Clin Oncol201232Suppl 155s
   Web of Science ®Google Scholar
• HurwitzHIUppalNWagnerSARandomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failedJ Clin Oncol201533344039404726351344
   PubMed Web of Science ®Google Scholar
• ClarkCEBeattyGLVonderheideRHImmunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancerCancer Lett200927911719013709
   PubMed Web of Science ®Google Scholar
• LeDTWang-GillamAPicozziVSafety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancerJ Clin Oncol201533121325133325584002
   PubMed Web of Science ®Google Scholar
• TsaiCSParkJWChenLTNanovector-based therapies in advanced pancreatic cancerJ Gastrointest Oncol20112318519422811849
   PubMedGoogle Scholar
• BertrandNWuJXuXKamalyNFarokhzadOCCancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biologyAdv Drug Deliv Rev20146622524270007
   PubMed Web of Science ®Google Scholar
• HyodoKYamamotoESuzukiTKikuchiHAsanoMIshiharaHDevelopment of liposomal anticancer drugsBiol Pharm Bull201336570370723649329
   PubMed Web of Science ®Google Scholar
• MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res19864612 Pt 1638763922946403
   PubMed Web of Science ®Google Scholar
• SeniorJHFate and behavior of liposomes in vivo: a review of controlling factorsCrit Rev Ther Drug Carrier Syst1987321231933542245
   PubMed Web of Science ®Google Scholar
• StathopoulosGPBoulikasTVougioukaMRigatosSKStathopoulosJGLiposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I–II studyOncol Rep20061551201120416596187
   PubMed Web of Science ®Google Scholar
• LoehrMBodokyGFölschUCationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial [abstract 4526]J Clin Oncol200927Suppl15s
   Google Scholar
• PommierYTopoisomerase I inhibitors: camptothecins and beyondNat Rev Cancer200661078980216990856
   PubMed Web of Science ®Google Scholar
• KawatoYAonumaMHirotaYKugaHSatoKIntracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11Cancer Res19915116418741911651156
   PubMed Web of Science ®Google Scholar
• ColbernGTDykesDJEngbersCEncapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenograftsClin Cancer Res1998412307730829865923
   PubMed Web of Science ®Google Scholar
• EmersonDLBendeleRBrownEAntitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecanClin Cancer Res2000672903291210914740
   PubMed Web of Science ®Google Scholar
• MessererCLRamsayECWaterhouseDLiposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancerClin Cancer Res200410196638664915475454
   PubMed Web of Science ®Google Scholar
• DrummondDCNobleCOGuoZHongKParkJWKirpotinDBDevelopment of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategyCancer Res20066663271327716540680
   PubMed Web of Science ®Google Scholar
• HannBPethKWangDLipidic nanoparticle CPT-11 in a bioluminescent orthotopic pancreas cancer model [abstract 5648]Paper presented at: AACR Annual MeetingApril 14–18, 2007Los Angeles, CA
   Google Scholar
• KalraAVKimJKlinzSGPreclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversionCancer Res201474237003701325273092
   PubMed Web of Science ®Google Scholar
• ChangTCShiahHSYangCHPhase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsCancer Chemother Pharmacol201575357958625577133
   PubMed Web of Science ®Google Scholar
• ChenLShiahHChaoTPhase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors [abstract e13024]J Clin Oncol201028Suppl 15
   Web of Science ®Google Scholar
• ChenLShiahHLinPPhase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy [abstract 613]J Clin Oncol201230Suppl 4
   Web of Science ®Google Scholar
• ChibaudelBMaindrault-GoebelFAndréTPEPCOL: a randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer – a GERCOR Study [abstract 751]J Clinical Oncol201533Suppl 3
   Web of Science ®Google Scholar
• RoyACParkSRCunninghamDA randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaAnn Oncol20132461567157323406728
   PubMed Web of Science ®Google Scholar
• Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJ Clin Oncol200422183776378315365074
   PubMed Web of Science ®Google Scholar
• StathopoulosGPSyrigosKAravantinosGA multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBr J Cancer200695558759216909140
   PubMed Web of Science ®Google Scholar
• KoAHTemperoMAShanYSA multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancerBr J Cancer2013109492092523880820
   PubMed Web of Science ®Google Scholar
• von HoffDDhindsaNBayeverENAPOLI-1: randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy [abstract]Ann Oncol201425Suppl 2ii105ii117
   Google Scholar
• ChenLVon HoffDLiCExpanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer previously treated with gemcitabine-based therapy [abstract 234]J Clin Oncol201533Suppl 3
   Web of Science ®Google Scholar
• PalomakiGEBradleyLADouglasMPKolorKDotsonWDCan UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based reviewGenet Med2009111213419125129
   PubMed Web of Science ®Google Scholar
• ClarkeJMolinaroADeSilvaAA phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas [abstract 2029]J Clin Oncol201533Suppl 15
   Web of Science ®Google Scholar
• YiSYParkYSKimHSIrinotecan monotherapy as second-line treatment in advanced pancreatic cancerCancer Chemother Pharmacol20096361141114518839175
   PubMed Web of Science ®Google Scholar
• TakaharaNNakaiYIsayamaHUridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancerCancer Chemother Pharmacol2013711859223053265
   PubMed Web of Science ®Google Scholar
• TaiebJLecomteTAparicioTFOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II studyAnn Oncol200718349850317158774
   PubMed Web of Science ®Google Scholar
• YooCHwangJYKimJEA randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerBr J Cancer2009101101658166319826418
   PubMed Web of Science ®Google Scholar
• GebbiaVMaielloEGiulianiFBorsellinoNArcaraCColucciGIrinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia MeridionaleAm J Clin Oncol201033546146420142727
   PubMed Web of Science ®Google Scholar
• CeredaSReniMRognoneAXELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancerAnticancer Res201030114785479021115942
   PubMed Web of Science ®Google Scholar
• ZaniboniAAitiniEBarniSFOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II studyCancer Chemother Pharmacol20126961641164522576338
   PubMed Web of Science ®Google Scholar
• NeuzilletCHenticORousseauBFOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-saltsWorld J Gastroenterol201218334533454122969226
   PubMed Web of Science ®Google Scholar
• MizunoNYamaoKKomatsuYRandomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer [abstract 263]J Clin Oncol201330Suppl 4
   Google Scholar